MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy

被引:237
作者
Ljungberg, Michael [1 ]
Celler, Anna [2 ]
Konijnenberg, Mark W. [3 ]
Eckerman, Keith F. [4 ]
Dewaraja, Yuni K. [5 ]
Sjogreen-Gleisner, Katarina
Bolch, Wesley E.
Brill, A. Bertrand
Fahey, Frederic
Fisher, Darrell R.
Hobbs, Robert
Howell, Roger W.
Meredith, Ruby F.
Sgouros, George
Zanzonico, Pat
Bacher, Klaus
Chiesa, Carlo
Flux, Glenn
Lassmann, Michael
Strigari, Lidia
Walrand, Stephan
机构
[1] Lund Univ, Dept Med Radiat Phys, SE-22185 Lund, Sweden
[2] Univ British Columbia, Dept Radiol, Med Imaging Res Grp, Vancouver, BC, Canada
[3] Erasmus Univ, Med Ctr, Dept Nucl Med, Rotterdam, Netherlands
[4] Easterly Sci, Knoxville, TN USA
[5] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI USA
基金
瑞典研究理事会;
关键词
image processing; oncology; endocrine; radiobiology/dosimetry; radionuclide therapy; SPECT/CT; guideline; lutetium; quantitative SPECT; RADIOLABELED SOMATOSTATIN ANALOG; RECEPTOR RADIONUCLIDE THERAPY; NEUROENDOCRINE TUMORS; INDIVIDUALIZED DOSIMETRY; 3-DIMENSIONAL DOSIMETRY; ACTIVITY QUANTIFICATION; MONOCLONAL-ANTIBODY; SCATTER CORRECTION; MEMBRANE ANTIGEN; DOSE ASSESSMENT;
D O I
10.2967/jnumed.115.159012
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The accuracy of absorbed dose calculations in personalized internal radionuclide therapy is directly related to the accuracy of the activity (or activity concentration) estimates obtained at each of the imaging time points. MIRD Pamphlet no. 23 presented a general overview of methods that are required for quantitative SPECT imaging. The present document is next in a series of isotope-specific guidelines and recommendations that follow the general information that was provided in MIRD 23. This paper focuses on Lu-177 (lutetium) and its application in radiopharmaceutical therapy.
引用
收藏
页码:151 / 162
页数:12
相关论文
共 67 条
[1]  
[Anonymous], NUDAT2 6
[2]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[3]   Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system [J].
Beauregard, Jean-Mathieu ;
Hofman, Michael S. ;
Pereira, Jucilene M. ;
Eu, Peter ;
Hicks, Rodney J. .
CANCER IMAGING, 2011, 11 (01) :56-66
[4]   Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors [J].
Bodei, Lisa ;
Cremonesi, Marta ;
Ferrari, Mahila ;
Pacifici, Monica ;
Grana, Chiara M. ;
Bartolomei, Mirco ;
Baio, Silvia M. ;
Sansovini, Maddalena ;
Paganelli, Giovanni .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) :1847-1856
[5]   Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors [J].
Bodei, Lisa ;
Kidd, Mark ;
Paganelli, Giovanni ;
Grana, Chiara M. ;
Drozdov, Ignat ;
Cremonesi, Marta ;
Lepensky, Christopher ;
Kwekkeboom, Dik J. ;
Baum, Richard P. ;
Krenning, Eric P. ;
Modlin, Irvin M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) :5-19
[6]  
Brolin G, 2014, 5 INT S TARG RAD THE
[7]   Evaluation of dead-time corrections for post-radionuclide-therapy 177Lu quantitative imaging with low-energy high-resolution collimators [J].
Celler, Anna ;
Piwowarska-Bilska, Hanna ;
Shcherbinin, Sergey ;
Uribe, Carlos ;
Mikolajczak, Renata ;
Birkenfeld, Bozena .
NUCLEAR MEDICINE COMMUNICATIONS, 2014, 35 (01) :73-87
[8]   Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters [J].
Cheng, Lishui ;
Hobbs, Robert F. ;
Segars, Paul W. ;
Sgouros, George ;
Frey, Eric C. .
PHYSICS IN MEDICINE AND BIOLOGY, 2013, 58 (11) :3631-3647
[9]  
Cherry S. R., 2003, PHYS NUCL MED
[10]  
Cremonesi M, 2011, Q J NUCL MED MOL IM, V55, P155